LYSOGENE was founded in 2009, by Karen Aiach and Olivier Danos, with a focused scientific development plan, pragmatic approach and bold mission. The company has been built on a comprehensive understanding of the impact of neurodegenerative diseases on patients and families.
Today, Lysogene is a fast growing biopharmaceutical company.
Lysogene finalized preparations, completes manufacturing and received IND clearance for its MPS IIIA clinical trial.
Sarepta and Lysogene signed an exclusive license agreement for LYS-SAF302 gene therapy for the treatment of MPS IIIA.
Lysogene successfully completed its IPO on Euronext Paris in February, raising approximately EUR24.6 million to finance its most important research and development projects.
Lysogene begins global observational study as it prepares to initiate pivotal clinical trial for the treatment of Sanfilippo Type A.
Lysogene enters into a strategic collaboration with the University of Massachusetts Medical School (UMMS) and Auburn University (AU) Alabama to develop IND-supporting pre-clinical studies in GM1-gangliosidosis using adeno-associated virus (AAV) gene therapy technology.
|Lysogene closes a €16.5m financing round with the French venture capital firm Sofinnova Partners, BPI France's Innobio and Novo Seeds. The financing raised will be used to expand clinical studies in MPS IIIA to achieve marketing approval. The funds will also allow the expansion of the pipeline to other genetic diseases affecting the central nervous system.|
|Lysogene successfully completes its gene therapy phase I/II clinical trial, with its lead product, in children with MPS IIIA (Tardieu et al. 2014).|
The US FDA approves Lysogene’s orphan drug application in MPS IIIA.
|The last two patients are included into the phase I/II clinical trial for MPS IIIA.|
At the end of the study all participants are invited to enter into a 4-year extension study.
|Lysogene is authorised by the French AFSSAPS to launch the first pediatric, intracerebral administered gene therapy in Europe. The first two patients receive investigational therapy.|
|The European Medicines Agency approves Lysogene’s orphan drug designation for its most advanced product, AAV vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase (hSGSH), intended to treat MPS IIIA.|
|Founded in France, Lysogene invests into the biotechnology field specializing in gene therapy targeting rare, neurodegenerative diseases. The company launches its development plan and regulatory toxicological studies for mucopolysacchardidosis type IIIA (MPS IIIA).|